Moderna says its COVID-19 vaccine is expected to protect against new variants
Laboratory experiments that tested Moderna's COVID-19 vaccine against new variants of the novel coronavirus show little to no impact on its efficacy, according to a press release from the company.
The vaccine produced antibodies that neutralized all key emerging variants tested, including B117 and B1351, which were first identified in the United Kingdom and in South Africa, respectively. The study showed "no significant impact" on neutralizing titers against the B117 variant. Meanwhile, a six-fold reduction in neutralizing titers was observed with the B1351 variant but remain above levels that are expected to be protective, according to the press release.
Although the two-dose regimen of the vaccine is expected to be protective against emerging strains to date, Moderna announced Monday that it will test two additional strategies: one to explore whether adding an extra dose could offer more protection, and another to study a version of their original vaccine that's more tailored to the South Africa variant.
"As we seek to defeat the COVID-19 virus, which has created a worldwide pandemic, we believe it is imperative to be proactive as the virus evolves. We are encouraged by these new data, which reinforce our confidence that the Moderna COVID-19 Vaccine should be protective against these newly detected variants," Moderna CEO Stephane Bancel said in a statement. "Out of an abundance of caution and leveraging the flexibility of our mRNA platform, we are advancing an emerging variant booster candidate against the variant first identified in the Republic of South Africa into the clinic to determine if it will be more effective to boost titers against this and potentially future variants."
ABC News' Sony Salzman contributed to this report.